SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma informs about acquisition

23 Jul 2025 Evaluate
Natco Pharma has informed that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business: To acquire 51,643,319 Shares (5,03,51,444 Ordinary Shares from public and 12,91,875 Treasury Shares/Fresh Issuance from Adcock Ingram Holdings Limited) at a cash offer of ZAR 75.00 (approximately US$ 4.27) per share i.e., 35.75% (inclusive of prior to acquisition shareholding of 0.80%) of shares of the Adcock Ingram Holdings Limited (“Adcock”), South Africa, with a total investment cost of approx. ?2000,00,00,000/- (Rupees Two Thousand Crores only) including the transaction cost and other expenses; To incorporate a wholly owned subsidiary in South Africa with an investment up to an amount not exceeding Rs.2100,00,00,000 (Rupees Two Thousand One Hundred Crores only) in the name of NATCO Pharma South Africa Proprietary Limited; To liquidate M/s. Time Cap Overseas Limited (TCOL), Wholly Owned Subsidiary of the Company and directly holds the investment in NatcoFarma do Brasil Ltda., which is a step down wholly owned subsidiary of Natco Pharma Limited. The brief disclosure under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as annexure. A Copy of Press release is also enclosed. The meeting commenced at 2.30 pm and concluded at 3.30 pm.

The above information is a part of company’s filings submitted to BSE.

Natco Pharma Share Price

1118.95 31.25 (2.87%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×